Drug intelligence / Profile preview

TMS-007

Development stage: Unknown
Lead developer: JIXING
Modality: Small Molecules
Administration: Intravenous

Overview

TMS-007 is a small molecule SMTP (Stachybotrys microspora triprenyl phenol) derivative being developed for the treatment of acute ischemic stroke. It functions as a plasminogen modulator that enhances the activation of plasminogen to plasmin, specifically in the presence of fibrin, thereby promoting thrombolysis. Additionally, it exhibits anti-inflammatory properties by inhibiting soluble epoxide hydrolase (sEH). Originally developed by TMS Co., Ltd., the compound was previously licensed to Biogen (as BIIB131) before the rights were returned to TMS in 2022. It aims to extend the therapeutic window for stroke treatment compared to traditional thrombolytics like tPA by reducing the risk of symptomatic intracranial hemorrhage.

Other names: SMTP-7SMTP7SMTP 7

Targets

EPHX2 (Soluble epoxide hydrolase)PLG (Plasminogen)

Beyond the preview

Go deeper on TMS-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TMS-007.

Explore the full profile